Home/Cases/TIGIT Class Context

TIGIT Class Context

Immuno-oncologyFragility
Fragility: Moderate to HighConfidence Risk: Elevated

A class-level pre-trial case showing that supportive TIGIT signals did not automatically add up to a stable class-wide escalation claim.

Public-evidence-bounded assessment

Pre-trial date-locked; no hindsight

Class enthusiasm becomes dangerous when support is counted faster than contradiction.

Opening frame

What this case actually shows

TIGIT class context matters because some mistakes happen one layer above the individual trial. The issue here is structural.

A platform story can feel coherent long before it has actually survived contradiction, context dependence, and target-class instability. Once that happens, class excitement begins to masquerade as class resolution.

Section 02

Why Class Narratives Mislead

Multiple data points, repeated checkpoint logic, and class-level excitement created the appearance of accumulating certainty. The narrative benefited from familiarity: the checkpoint framework already felt legible, so every supportive point could be read as one more sign that the class was maturing into something stable.

That is exactly the kind of environment in which a class thesis can become too smooth too early.

Class stories become dangerous because they let the field borrow coherence from multiple adjacent signals without fully adjudicating whether those signals actually converge. Momentum starts to look like validation, and supportive examples begin doing the work that contradiction should be doing.

That is how a platform thesis becomes emotionally convincing before it becomes scientifically disciplined.

Section 03

Where the Class Boundary Lived

The class narrative stayed vulnerable to selective reading because contradiction was not yet being weighted as heavily as support.

That meant the class looked more converged than it really was. The underlying problem was not lack of interesting signal, but unresolved breadth and unresolved portability.

The real boundary lived at portability. A class thesis deserves scale only when it remains stable across contradictory evidence, varying tumor contexts, and unresolved mechanistic breadth.

Before that, it is still a conditional story wearing the language of convergence. This is the exact place where many class narratives become more persuasive than they are resolved.

Class enthusiasm becomes dangerous when support is counted faster than contradiction.

Section 04

What was missed

A platform thesis is not validated by momentum. It has to survive a disciplined contradiction audit.

The miss here was allowing supportive pieces to accumulate into a confidence posture before the class had actually proven it could remain coherent under harder evidence pressure.

Single cases alone are not enough to teach this lesson. Some mistakes happen at the class level, where the error is not one trial design but an entire narrative becoming more settled than the underlying evidence has earned.

That is why this page belongs in the archive: it teaches readers how to audit a platform thesis, not just an individual program.

Section 05

What should have been tested

The pre-trial question was whether the class-level confidence still held once failures, heterogeneous contexts, and unresolved mechanistic portability were treated as central evidence.

In other words, would the class story still look stable if contradiction were given equal status to support?

What this changes

How this should affect the next decision

The implication is not simply that the program looked fragile. The implication is that escalation confidence should have narrowed until the unresolved boundary was tested directly.

In practice, that means a serious team should treat this as a prompt to refine the claim, restrict the confidence posture, and resolve the highest-yield uncertainty before the next irreversible move.

Why this matters

This case edition is free for learning. For live programs, the same question has to be answered with confidential program-specific evidence, not public approximation alone.

Representative References

Pre-trial sources used to anchor the case boundary

These references are representative of the evidence landscape available before the escalation boundary. Later outcome knowledge is excluded from the interpretive frame.

  1. Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic NSCLCMajor contradiction event for TIGIT class confidence.
  2. Roche provides update on Phase III SKYSCRAPER-01 study in PD-L1-high metastatic NSCLCFurther class-relevant signal showing unresolved durability and OS uncertainty.
  3. Roche tiragolumab receives Breakthrough Therapy Designation in PD-L1-high NSCLCUseful pre-contradiction source for how TIGIT enthusiasm built at the class level.

Archive Boundary

Free for learning. Separate for live decisions.

This page is part of the public archive. For live programs, analysis is conducted separately under strict confidentiality and with program-specific evidence where available.